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Psychotic symptoms in Parkinson’s disease (PD) are frequent, disabling, and an important prognostic factor. Thus, screening
instrumentsfordetectingpsychosisinPDareneeded.Forthispurpose,weappliedtheParkinson’sPsychosisQuestionnaire(PPQ),
a short structured questionnaire, which requires no speciﬁc training, along with the Brief Psychiatric Rating Scale, expanded
version (BPRS-E), for rating general psychopathology, including psychotic symptoms. We evaluated, in a cross-sectional study, a
Portuguese sample of 36 early-stage PD patients (mean age of 73 years; mean duration of illness of 3.2 years). The PPQ total score
correlated with the BPRS-E total score (0.359; P = 0.032) and with the BPRS-E-positive symptoms score (0.469; P = 0.004). The
prevalence of psychosis (41.7%) was higher than expected. Sampling bias and detection of minor psychotic phenomena may have
contributed to this result. These ﬁndings suggest that the PPQ should be further evaluated as a feasible assessment for psychotic
symptoms in PD.
1.Introduction
InthecontextofParkinson’sdisease(PD),thetermpsychosis
usually referred to a mental state characterized by hallucina-
tions and/or delusions, occurring with a clear sensorium and
a chronic course. In the past years, deﬁnitions have chang-
ed and the typical hallucinatory syndrome in PD now en-
compasses other related phenomena, such as minor phe-
nomena, like illusions, sense of presence, and passage hal-
lucinations [1].
Among the nonmotor features of Parkinson’s disease
(PD), psychotic symptoms are frequent, ranging from 20 to
30% of patients [2]. Over the course of PD, psychotic symp-
toms, once present, tend to be persistent and progressive [3].
The impact of psychosis is substantial in that it is associated
with dementia, depression, earlier mortality, greater care-
giver strain, and nursing home placement. Psychosis also has
important treatment implications, as it limits the therapy of
motor symptoms [4].
Recently, the Task Force of the Movement Disorder Soci-
ety comprehensively reviewed the scales used to assess psy-
chosis in PD [5]. Albeit none of the current scales has been
shown to possess the necessary basic mechanistic and psy-
chometric properties, it was suggested that, in the meantime,
the selection of the current scales should be based on the
goals of the assessment [5]. Therefore and aiming for a
precociousdetectionofpsychoticsymptomsinPD,especially
in early stage patients, we were interested in exploring2 Parkinson’s Disease
easy-to-use instruments and we selected the Parkinson’s Psy-
chosis Questionnaire (PPQ) [2, 5]. It is a brief, structured
instrument that was designed for screening psychotic symp-
toms in PD patients.
We set out to compare the use of a brief and structured
screening tool for psychosis in PD, the PPQ, and of the Brief
Psychiatric Rating Scale, expanded version (BPRS-E), as a
gold standard [6].
2.MaterialandMethods
2.1.StudyType,Sample,andLocation. Thestudyhadacross-
sectional design. The sample consisted of 36 consecutive
patients (19 females and 17 males) with early stage PD, re-
cruited from Hospital Egas Moniz Neurology Department’s
outpatient clinic (Lisbon, Portugal). None of the patients
refused to enter the study.
To be included, patients were required to have less than
5 years of disease duration since the ﬁrst motor symptoms
were reported and a Hoehn and Yahr stage [7] from 1 to 2.5.
Informed consent was obtained from all patients. Patients
with diseases of the central nervous system other than PD
were excluded from the study.
2.2. PD Diagnosis. PD was diagnosed by P.B., an experienced
movement disorder specialist, according to validated clinical
criteria [8].
2.3. Demographics and Clinical Variables. Patients’ demo-
graphical data (gender, age, and education level) and clinical
data (duration of illness, levodopa equivalent dose, Hoehn
and Yahr stage) were collected. The method for converting
the total daily dopaminergic therapeutic dose in levodopa
equivalent dose was obtained from published formulas [9].
The evaluation of the patients’ cognition was made using
the Portuguese version of the Mini-Mental State Examin-
ation (MMSE) from Guerreiro et al. [10]. MMSE is a simple,
widely used scale to detect cognitive impairment. Although
there is a debate on its usefulness as a screening tool for
cognitive impairment in PD [11], it may still be considered
appropriate for this purpose [5, 12]. In addition, the Frontal
Assessment Battery (FAB) was applied for the same purpose
[10]. FAB is a rapid screening battery that has been validated
for PD [13–15].
2.4. Evaluation of Psychosis/Psychotic Symptoms. Psychiatry
trainees (I.C., M.S., J.A.S., and B.N.) assessed the patients
for psychotic symptoms, using two diﬀerent instruments: a
structured and easy-to-administer questionnaire that specif-
ically addresses psychotic and related symptoms in PD—
the PPQ [2]—and a widely used general psychopathology
semistructured instrument—the BPRS-E [6].
The PPQ was developed as a 14-item screening instru-
ment for early recognition of psychosis in PD. The speciﬁcity
andsensitivityreportedbythedevelopersofPPQwere92.1%
and 100%, respectively, using Structured Clinical Interview
for DSM-IV-TR Axis I Disorders (SCID) as the gold stand-
ard [2]. This scale includes probe questions followed by
detailed questions regarding four domains. The ﬁrst domain
includes three questions about the presence or absence of
sleep disturbance. The following domain assesses, in four
questions, the occurrence of hallucinations and/or illusions,
including visual, auditory, and tactile hallucinations. The
third domain includes ﬁve questions to detect diﬀerent types
ofdelusions:persecutory,jealousy,poisoning,abandonment,
and control. The fourth domain assesses place and time
orientation. Within a domain, any positive answer triggers
inquiries about frequency (1–3 points) and severity (1–3
points). Each subscore is the product of the frequency multi-
plied by the severity score for that symptom domain. The
total score is obtained by summing all subscores. PPQ case-
ness is deﬁned by at least a positive score on the domains
of hallucinations/illusions and/or delusions. We used our
Portuguese translation of the PPQ. Two English-ﬂuent med-
ical doctors among the authors (BN, JAS) were responsible
for this translation. Given the simple straightforward nature
of the translation process, backtranslation procedures were
skipped. Moreover, face and content validity of the original
version are assumed to be preserved.
The BPRS-E [6, 16] was designed for measuring overall
psychopathological change in patients with schizophrenia.
Validity and reliability have been widely documented [6,
16, 17]. It is administered in a semistructured manner, and
it takes about 30 minutes to complete. It comprehends 24
items that can be scored from 1 (not present) to 7 (very
severe). The total BPRS-E score is the sum of the scores for
each of the 24 items. A Portuguese translation (Caldas de
Almeida, Gusm˜ ao, Talina, and Xavier—Universidade Nova
de Lisboa, 1996; unpublished document) of the BPRS-E was
used. Since there is no study describing the factor structure
of BPRS-E for PD, we used a BPRS-E factor solution that
was described in a sample of European patients with schizo-
phrenia [17] and recently used in Portuguese research
[18]. This factor solution includes four subscales: positive
symptoms (grandiosity, suspiciousness, hallucinations, un-
usual thought content, and conceptual disorganisation),
negative symptoms (disorientation, blunted aﬀect, emotion-
al withdrawal, motor retardation, self-neglect, uncoopera-
tiveness, mannerism, and posturing), manic excitement/dis-
organization items (hostility, elevated mood, bizarre behav-
iour, self-neglect, uncooperativeness, excitement, distrac-
tibility, motor hyperactivity, mannerism and posturing), and
depression/anxiety components (anxiety, depression, suici-
dality, guilt content, somatic concern, and tension). The sub-
scales score is the sum of the scores for each item within a
subscale. In this paper, mean scores (1 to 7) are presented for
total BPRS-E and subscale scores.
Assessments with the BPRS-E and PPQ were conducted
by the same interviewer for each patient. However, to mini-
mizethebiasrelatedtothelackofoccultation,thesemistruc-
tured instrument (BPRS) was applied ﬁrst. Each psychiatric
trainee evaluated approximately 25% of the sample.
2.5. Statistical Analysis. Due to small sample size and the
lack of a normal distribution in most continuous variables,
we chose to use a nonparametric statistical analysis. Mann-
Whitney test was used to compare the mean values of
the BPRS-E factors and levodopa equivalent dosages (LED)Parkinson’s Disease 3
Table 1: Sociodemographic and clinical data (n = 36).
Gender (male/female) 17/19
Age (years) 73.17 (6.54)∗
Education 4 (4)∗
Duration of illness (years) 3.17 (1.30)∗
Levodopa equivalent dose (mg) 300∗∗ (range 0–1500)
Hoehn and Yahr stage (on) 2∗∗ (range 1–3)
MMSE 27.22 (2.53)∗
FAB 13.31 (3.13)∗
PPQ (total score) 3.69 (3.42)∗ (range 0–12)
PPQ (% cases) 41.7
BPRS (total score)+ 1.26 (0.16)∗
BPRS (positive symptoms score)+ 1.24 (0.31)∗
BPRS (negative symptoms score)+ 1.19 (0.24)∗
BPRS (depression/anxiety score)+ 1.60 (0.54)∗
BPRS (mania/hostility score)+ 1.04 (0.05)∗
∗mean (standard deviation).
∗∗median.
+weighted scores; range 1 (not present) through 7 (extremely severe).
between PPQ cases and noncases. The Spearman’s rank
correlation coeﬃcient was used to evaluate the association
strength between LED and psychotic symptoms severity and
also between PPQ scores and BPRS-E scores. The level of
statistical signiﬁcance was set at P ≤ 0.05.
All statistical analyses were performed using SPSS 18.0.
(SPSS, Inc., Chicago, IL).
3. Results andDiscussion
3.1. Results. The clinical and demographical characteristics
of the 36 patients in the sample are summarized in Table 1.
Thirty-two patients were on dopaminergic treatment: 17
on levodopa only, 6 exclusively on dopaminergic agonists,
and 9 on both types of drugs. Amantadine was not used and
neither neuroleptic nor cholinesterase inhibitors.
Consideringthewholesample,LEDshowedacorrelation
trend, although with a low level of evidence, with PPQ total
score (rs = 0.311; P = 0.065), and BPRS-E positive sym-
ptoms (rs = 0.322; P = 0.056). There was no evidence of cor-
relation between LED and the other BPRS-E factor scores, or
between LED and the Total BPRS-E score.
Fifteen patients were deﬁned as cases by the PPQ. Of
these, 4 reported the presence of illusions but not of major
psychotic phenomena. In fact, as these psychotic symptoms
were not disturbing to the patients, they did not lead to any
speciﬁc changes in the management of the patients.
Although the mean LED was higher in PPQ cases than
in noncases, this diﬀerence was not statistically signiﬁcant
after correcting for multiple comparisons (Table 2). MMSE
and FAB scores were similar between cases and noncases.
Mean scores of the BPRS subscales did not diﬀer in PPQ
cases and noncases, except for the positive symptom subscale
scores, which were higher in the cases’ group (Table 2).
The PPQ total score was signiﬁcantly correlated with
total BPRS-E and positive symptoms BPRS-E scores
(Table 3).
3.2. Discussion. Prevalence of psychotic symptoms in PD is
variable among diﬀerent studies. Cross-sectional studies of
clinical populations have reported prevalences as disparate
as 25% [19] and 75% [20]. This may be due to diﬀerences
regarding the type of psychotic phenomena assessed, dif-
ferent diagnostic criteria, and other methodological issues.
Williams et al. [20], for instance, encompassed minor psy-
chotic phenomena in their deﬁnition of psychosis and
identiﬁed them in a large majority (72%) of their PD
patients. However, this study was not limited to early stage
patients.
In our study, minor psychotic phenomena were respon-
sible for the deﬁnition of approximately one quarter of cases.
This could help to explain the high prevalence of psychotic
symptoms found in our sample of patients with early stage
PD. Furthermore, Graham et al. [19] described that the
proportion of hallucinations did not increase in a linear
fashion with PD progression. They found that there was a
peak of onset of perceptual disturbances during the ﬁrst ﬁve
years of disease. However, subsequent longitudinal studies
did not conﬁrm this ﬁnding [21].
An u m b e ro fs t u d i e sh a v ea l s os u g g e s t e dt h a td e m o -
graphic factors, like age, could be related to a high prevalence
of hallucinations in an early stage population, independent
of disease duration [22, 23]. Actually, the majority of our
patients were aged and that may have contributed to a higher
prevalence of psychotic symptoms in our sample.
Sampling bias could have also contributed to these
results: ﬁrst, our sample was not randomized; second, one
may argue that early PD patients with manifest psychotic
symptoms are more easily referred to a neurology outpatient
clinic.
LED was not signiﬁcantly associated with psychotic
symptoms in this sample. The relation of dopaminergic
treatment with psychotic symptoms in PD is still a matter
of debate. Data on untreated patients with early PD is scarce
and conﬂicting [4]. Furthermore, several cross-sectional
studies could not identify diﬀerences in LED between pa-
tients with and without hallucinations [4] .H o w ev e r ,ar e c e n t
meta-analysis [24] reported that dopamine agonists were
associated with higher odds of experiencing hallucinations,
when compared with both placebo and levodopa. Dopamin-
ergictreatmentmaybeanimportantriskfactorforpsychotic
symptoms in PD, as hallucinations in drug-free PD patients
areveryrare.Infact,noneofourdrugfreepatientspresented
with hallucinations. We were not able, though, to evaluate
the association of diﬀerent treatment proﬁles with psychosis
because of the small number of patients in each group
(levodopa, dopaminergic agonists, or both).
A longitudinal study found that cognitive impairment in
early PD predicted the development of psychotic symptoms
with treatment [25]. In this cross-sectional scenario, we were
notabletoreproduceanassociationbetweencognitivescores
and the presence of psychosis according to the PPQ case
deﬁnition.4 Parkinson’s Disease
Table 2: Comparison of levodopa equivalent dose and BPRS scores between PPQ cases and noncases.
PPQ non-cases mean
(standard deviation)
PPQ cases mean
(standard deviation)
Adjusted+ P value
(Mann-Whitney test)
Levodopa equivalent dose 302.38 (377.07) 527.00 (363.73) 0.336
MMSE 27.33 (2.9) 27.07 (1.9) >1
FAB 11.67 (3.12) 10.80 (3.19) >1
BPRS—total score 1.23 (0.16) 1.31 (0.16) >1
BPRS—positive symptoms 1.10 (0.16) 1.43 (0.37) 0.016
BPRS—negative symptoms 1.15 (0.24) 1.24 (0.23) 0.936
BPRS—mania/disorganization 1.04 (0.06) 1.03 (0.051) >1
BPRS—depression/anxiety 1.62 (0.57) 1.57 (0.51) >1
+Bonferroni correction was used to correct for multiple comparisons.
Table 3: Correlations between PPQ total score and BPRS scores
(total and subscale scores). Spearman’s rank correlation coeﬃcient
was used (n = 36).
PPQ total score
BPRS (total score) 0.359; P = 0.032
BPRS (positive symptoms score) 0.469; P = 0.004
BPRS (negative symptoms score) 0.124; P = 0.472
BPRS (depression/anxiety score) 0.205; P = 0.231
BPRS (mania/hostility score) −0.109; P = 0.528
Albeit not above moderate levels, an association was
found between the PPQ scores and the BPRS-E scores.
Interestingly, this association was only evident concerning
the BPRS-E total score and the positive symptoms subscale
score, which includes the psychotic symptoms most often
reported in PD. In fact, BPRS-E-positive symptoms would
be expected to correspond grosso modo to the hallucina-
tion/illusionanddelusionalcategoriesofthePPQ.Moreover,
PPQ cases presented signiﬁcantly higher scores of BPRS-E
positive symptoms when compared to noncases. Therefore,
there is an argument to further explore the use of the PPQ
for PD psychosis both in research and clinical settings.
Along with selection bias, the main limitations of this
study are the small sample size and the lack of a control
group. Furthermore, our evaluation did not include follow-
up data. Regarding assessments, we had no previous knowl-
edge of the detailed psychometric properties of the PPQ in
Portugal,andwepostulatedaBPRS-Efactorstructure,which
in fact was not originated in PD populations. Also, since the
BPRS-Eisaninstrumentthatprovidesacontinuousmeasure
ofpsychopathologyandisnotadiagnostictool,wecouldnot
calculate PPQ sensitivity and speciﬁcity in this population.
The fact that evaluations were not conducted blindly by the
interviewers, who used the PPQ and the BPRS in the same
patient, may have contributed to some bias. Nevertheless, by
applying the PPQ systematically after the BPRS, we tried to
reduce this bias. The structured nature of the PPQ would not
allow for any probing that could have been prompted by the
answers to the BPRS-E.
4. Conclusions
In this paper, we described a small nonrandomized sample
of early stage PD Portuguese outpatients, exploring PPQ
validity as related to BPRS-E results in the detection of PD
psychosis.
We found an acceptable agreement between PPQ and
BPRS-E assessments, and this supports, to some extent,
the PPQ as a feasible and valid screening instrument for
psychosis in PD, namely, in early stages of the disease. While
the PPQ is easily used and allows for quick administration
procedures, the BPRS-E remains a more demanding, semi-
structured instrument that requires speciﬁc training.
Easy and quick-to-use tools like PPQ, if valid in early PD,
may contribute to a precocious identiﬁcation of psychotic
symptoms and hopefully to a better clinical management of
patients with PD.
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